Blood cancers

Australian study provides insight into long-term efficacy of venetoclax in relapsed CLL

An extended follow-up on pooled data from four early-phase clinical trials of venetoclax in patients with previously treated CLL or small lymphocytic lymphoma has confirmed which patients are most likely to do well. The study, comprising 436 patients who had been heavily treated with a median of three prior therapies, found a three-year progression free ...

Already a member?

Login to keep reading.

© 2021 the limbic